TABLE 1.
Baseline characteristics
| Variables | cAMR (n = 49) | Control (n = 49) | P |
|---|---|---|---|
| Male n, (%) | 31 (63%) | 30 (61%) | 0.83 |
| Mean age transplant (years) | 45.0 ± 11.6 | 45.3 ± 11.6 | 0.87 |
| Caucasian n, (%) | 44 (90%) | 44 (90%) | |
| Causes of ESRD n, (%) | 0.08 | ||
| Glomerulonephritis | 19 (39%) | 10 (20%) | |
| Diabetes | 9 (18%) | 8 (17%) | |
| Hypertension | 4 (8%) | 5 (10%) | |
| PKD | 9 (18%) | 10 (20%) | |
| Other | 8 (17%) | 16 (33%) | |
| Mean number of transplants | 1.3 ± 0.6 | 1.4 ± 0.7 | 0.27 |
| Mean HLA mismatch (of 6) | 4.2 ± 1.1 | 4.2 ± 1.3 | 0.80 |
| Living donor transplant n, (%) | 20 (41%) | 22 (45%) | 0.68 |
| Induction therapy n, (%) | 0.19 | ||
| IL-2 receptor antibodies | 29 (60%) | 20 (41%) | |
| Antithymocyte globulin | 9 (18%) | 21 (43%) | |
| Alemtuzumab | 6 (12%) | 5 (10%) | |
| OKT3 | 1 (2%) | 0 | |
| Other/unknown | 4 (8%) | 3 (6%) |
ESRD, end-stage renal disease.